Business
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MD / ACCESS Newswire / October 7, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed","length":148,"tagName":"p"},{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / October 7, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced in-vitro findings for IGC-1C, a low-molecular weight compound. The data are consistent with IGC-1C acting as a modulator of the tau protein's liquid-liquid phase separation (LLPS), an emerging and critical pathway implicated in the earliest stages of Alzheimer's disease and related tauopathies.","length":592,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/8bd70ad518aa980098425ab4fa3f831f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fyDsy1vnD8D1OSohr9NAPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/8bd70ad518aa980098425ab4fa3f831f","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/W358d4JgU_7ytaEBB3U61g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/8bd70ad518aa980098425ab4fa3f831f","width":1200,"height":710}}},{"type":"text","content":"The LLPS pathway represents a potential paradigm shift in neurodegenerative research. When dysregulated, tau protein separates into liquid-like droplets, or condensates, which serve as the pathological "seeds" that mature into neurotoxic fibrillar aggregates (neurofibrillary tangles). By targeting the initial LLPS stage, IGC-1C offers the potential to halt the disease progression before irreversible damage occurs, a therapeutic approach distinct from late-stage plaque or tangle inhibitors.","length":504,"tagName":"p"},{"type":"text","content":""IGC-1C can potentially target a key and early pathological event in Alzheimer's disease. By intervening at the phase separation stage, we aim to prevent the formation of toxic tau aggregates, opening a novel and pot...